Company intelligence / Profile preview

Rua Bioscience

Gisborne / Ruatorea, Gisborne, New Zealand

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Rua Bioscience supplies GMP-certified cannabinoid medicines based on proprietary plant genetics. It is a pioneer in New Zealand medicinal cannabis and has established commercial supply agreements in Europe and Australia. Financially, it is focused on a capital-light model and is outsourcing commercial manufacturing. Clinical results and product uptake are not detailed in search results

Therapeutic areas: ImmunologyNeurologyOther
Modalities: Small moleculeBiologicPlant-derived therapies (cannabinoids)
Industry: Biotech

Partnerships

International supply agreement in EuropeGMP-certified manufacturing partnership in Australia (specific companies not named)

Beyond the preview

Go deeper on Rua Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rua Bioscience.

Explore the full profile